Next Article in Journal
Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients
Next Article in Special Issue
Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
Previous Article in Journal
Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019
Previous Article in Special Issue
Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
 
 
Article

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

1
Department of Nuclear Medicine, AP-HP Saint-Louis Hospital, F-75010 Paris, France
2
Department of Dermatology, AP-HP Saint-Louis Hospital, F-75010 Paris, France
3
Université Paris Cité, INSERM U976, F-75010 Paris, France
4
Université Paris Cité, F-75006 Paris, France
5
Université Paris Cité, INSERM UMR_S942, F-75006 Paris, France
*
Author to whom correspondence should be addressed.
Academic Editor: Peter Hersey
Cancers 2022, 14(13), 3190; https://doi.org/10.3390/cancers14133190
Received: 31 May 2022 / Revised: 20 June 2022 / Accepted: 22 June 2022 / Published: 29 June 2022
(This article belongs to the Collection Targeted Therapies and Immunotherapies in Metastatic Melanoma)
In a retrospective study of patients with advanced or metastatic melanoma treated with first-line immune checkpoint inhibitors, we investigated the value of metabolic criteria, PERCIST 5 (criteria used for conventional chemotherapy), and imPERCIST5 (criteria adapted for immunotherapy therapeutic evaluation). Responding patients according to both criteria had better overall survival than that of not-responding patients, with a 2 years OS of 91% versus 39%, respectively. Combining different approaches to assess response could help improve the confidence in the test aiming at evaluating the response to immunotherapy.
Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the potential contribution of total tumor metabolic volume (TMTV) analysis. Methods: We conducted a retrospective study in patients treated with first-line ICI for advanced or metastatic melanoma, with 18F-FDG PET/CT performed at baseline and 3 months after starting treatment. Patients’ metabolic response was classified according to PERCIST5 and imPERCIST 5 criteria. TMTV was recorded for each examination. Results: Twenty-nine patients were included. The median overall survival (OS) was 51.2 months (IQR 13.6—not reached), and the OS rate at 2 years was 58.6%. Patients classified as responders (complete and partial response) had a 90.9% 2-year OS rate versus 38.9% for non-responders (stable disease and progressive disease) (p = 0.03), for PERCIST5 and imPERCIST 5 criteria. The median change in metabolic volume was 9.8% (IQR −59–+140%). No significant correlation between OS and changes in TMTV was found. Conclusion: The evaluation of response to immunotherapy using metabolic imaging with PERCIST5 and imPERCIST5 was significantly associated with OS in patients with advanced or metastatic melanoma. View Full-Text
Keywords: FDG PET; melanoma; immunotherapy; therapeutic response; immune checkpoint inhibitors FDG PET; melanoma; immunotherapy; therapeutic response; immune checkpoint inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Rivas, A.; Delyon, J.; Martineau, A.; Blanc, E.; Allayous, C.; Da Meda, L.; Merlet, P.; Lebbé, C.; Baroudjian, B.; Vercellino, L. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers 2022, 14, 3190. https://doi.org/10.3390/cancers14133190

AMA Style

Rivas A, Delyon J, Martineau A, Blanc E, Allayous C, Da Meda L, Merlet P, Lebbé C, Baroudjian B, Vercellino L. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers. 2022; 14(13):3190. https://doi.org/10.3390/cancers14133190

Chicago/Turabian Style

Rivas, Alexia, Julie Delyon, Antoine Martineau, Estelle Blanc, Clara Allayous, Laetitia Da Meda, Pascal Merlet, Céleste Lebbé, Barouyr Baroudjian, and Laetitia Vercellino. 2022. "18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors" Cancers 14, no. 13: 3190. https://doi.org/10.3390/cancers14133190

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop